Cargando…

Durable Clinical Response to ALK Tyrosine Kinase Inhibitors in Epithelioid Inflammatory Myofibroblastic Sarcoma Harboring PRRC2B-ALK Rearrangement: A Case Report

Inflammatory myofibroblastic tumor (IMT) is a rare mesenchymal neoplasm and patients with IMT tend to have a favorable outcome after complete surgical resection. However, some tumors of IMT cases have recurred and grown rapidly after successful surgery. Epithelioid inflammatory myofibroblastic sarco...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zhan, Geng, Yan, Yuan, Ling-Yan, Wang, Miao-Miao, Ye, Chen-Yang, Sun, Li, Dai, Wei-Ping, Zang, Yuan-Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8882834/
https://www.ncbi.nlm.nih.gov/pubmed/35237506
http://dx.doi.org/10.3389/fonc.2022.761558
_version_ 1784659784595668992
author Wang, Zhan
Geng, Yan
Yuan, Ling-Yan
Wang, Miao-Miao
Ye, Chen-Yang
Sun, Li
Dai, Wei-Ping
Zang, Yuan-Sheng
author_facet Wang, Zhan
Geng, Yan
Yuan, Ling-Yan
Wang, Miao-Miao
Ye, Chen-Yang
Sun, Li
Dai, Wei-Ping
Zang, Yuan-Sheng
author_sort Wang, Zhan
collection PubMed
description Inflammatory myofibroblastic tumor (IMT) is a rare mesenchymal neoplasm and patients with IMT tend to have a favorable outcome after complete surgical resection. However, some tumors of IMT cases have recurred and grown rapidly after successful surgery. Epithelioid inflammatory myofibroblastic sarcoma (EIMS) is a highly aggressive intra-abdominal IMT variant with epithelioid-to-round cell morphology. Currently, no standard therapy exists for recurrent or invasive IMTs and EIMS, but anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) are recommended for those harboring ALK gene rearrangements. We herein report the first case of PRRC2B-ALK fusion associated IMTs with clinical and pathological manifestation matched the diagnosis criteria of EIMS and the durable clinical response of the sequential use of ALK TKIs (crizotinib, alectinib, ceritinib, and lorlatinib). A female patient with EIMS of the greater omentum was suffering from a rapid recurrence after cytoreductive surgery was done. Crizotinib was administered when PRRC2B-ALK fusion was detected, and partial response was achieved. The progression-free survival (PFS) of crizotinib was 5 months. Alectinib was administered based on the results of second next-generation sequencing (NGS) analysis, which identified the secondary mutation ALK R1192P. The best overall response of alectinib treatment was a partial response (PR) and the PFS was 5.5 months. Ceritinib was prescribed as third-line therapy after alectinib resistance with ALK L1196M mutation. PR was achieved and the PFS of ceritinib was 6 months. The patient was taking lorlatinib after ceritinib resistance and achieved a stable disease at 2 months with the PFS more than 5 months. The overall survival was more than two years as of the time of manuscript preparation. We describe an EIMS of greater omentum caused by PRRC2B-ALK fusion gene and showed durable clinical response to the sequential use of ALK TKIs.
format Online
Article
Text
id pubmed-8882834
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-88828342022-03-01 Durable Clinical Response to ALK Tyrosine Kinase Inhibitors in Epithelioid Inflammatory Myofibroblastic Sarcoma Harboring PRRC2B-ALK Rearrangement: A Case Report Wang, Zhan Geng, Yan Yuan, Ling-Yan Wang, Miao-Miao Ye, Chen-Yang Sun, Li Dai, Wei-Ping Zang, Yuan-Sheng Front Oncol Oncology Inflammatory myofibroblastic tumor (IMT) is a rare mesenchymal neoplasm and patients with IMT tend to have a favorable outcome after complete surgical resection. However, some tumors of IMT cases have recurred and grown rapidly after successful surgery. Epithelioid inflammatory myofibroblastic sarcoma (EIMS) is a highly aggressive intra-abdominal IMT variant with epithelioid-to-round cell morphology. Currently, no standard therapy exists for recurrent or invasive IMTs and EIMS, but anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) are recommended for those harboring ALK gene rearrangements. We herein report the first case of PRRC2B-ALK fusion associated IMTs with clinical and pathological manifestation matched the diagnosis criteria of EIMS and the durable clinical response of the sequential use of ALK TKIs (crizotinib, alectinib, ceritinib, and lorlatinib). A female patient with EIMS of the greater omentum was suffering from a rapid recurrence after cytoreductive surgery was done. Crizotinib was administered when PRRC2B-ALK fusion was detected, and partial response was achieved. The progression-free survival (PFS) of crizotinib was 5 months. Alectinib was administered based on the results of second next-generation sequencing (NGS) analysis, which identified the secondary mutation ALK R1192P. The best overall response of alectinib treatment was a partial response (PR) and the PFS was 5.5 months. Ceritinib was prescribed as third-line therapy after alectinib resistance with ALK L1196M mutation. PR was achieved and the PFS of ceritinib was 6 months. The patient was taking lorlatinib after ceritinib resistance and achieved a stable disease at 2 months with the PFS more than 5 months. The overall survival was more than two years as of the time of manuscript preparation. We describe an EIMS of greater omentum caused by PRRC2B-ALK fusion gene and showed durable clinical response to the sequential use of ALK TKIs. Frontiers Media S.A. 2022-02-14 /pmc/articles/PMC8882834/ /pubmed/35237506 http://dx.doi.org/10.3389/fonc.2022.761558 Text en Copyright © 2022 Wang, Geng, Yuan, Wang, Ye, Sun, Dai and Zang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Wang, Zhan
Geng, Yan
Yuan, Ling-Yan
Wang, Miao-Miao
Ye, Chen-Yang
Sun, Li
Dai, Wei-Ping
Zang, Yuan-Sheng
Durable Clinical Response to ALK Tyrosine Kinase Inhibitors in Epithelioid Inflammatory Myofibroblastic Sarcoma Harboring PRRC2B-ALK Rearrangement: A Case Report
title Durable Clinical Response to ALK Tyrosine Kinase Inhibitors in Epithelioid Inflammatory Myofibroblastic Sarcoma Harboring PRRC2B-ALK Rearrangement: A Case Report
title_full Durable Clinical Response to ALK Tyrosine Kinase Inhibitors in Epithelioid Inflammatory Myofibroblastic Sarcoma Harboring PRRC2B-ALK Rearrangement: A Case Report
title_fullStr Durable Clinical Response to ALK Tyrosine Kinase Inhibitors in Epithelioid Inflammatory Myofibroblastic Sarcoma Harboring PRRC2B-ALK Rearrangement: A Case Report
title_full_unstemmed Durable Clinical Response to ALK Tyrosine Kinase Inhibitors in Epithelioid Inflammatory Myofibroblastic Sarcoma Harboring PRRC2B-ALK Rearrangement: A Case Report
title_short Durable Clinical Response to ALK Tyrosine Kinase Inhibitors in Epithelioid Inflammatory Myofibroblastic Sarcoma Harboring PRRC2B-ALK Rearrangement: A Case Report
title_sort durable clinical response to alk tyrosine kinase inhibitors in epithelioid inflammatory myofibroblastic sarcoma harboring prrc2b-alk rearrangement: a case report
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8882834/
https://www.ncbi.nlm.nih.gov/pubmed/35237506
http://dx.doi.org/10.3389/fonc.2022.761558
work_keys_str_mv AT wangzhan durableclinicalresponsetoalktyrosinekinaseinhibitorsinepithelioidinflammatorymyofibroblasticsarcomaharboringprrc2balkrearrangementacasereport
AT gengyan durableclinicalresponsetoalktyrosinekinaseinhibitorsinepithelioidinflammatorymyofibroblasticsarcomaharboringprrc2balkrearrangementacasereport
AT yuanlingyan durableclinicalresponsetoalktyrosinekinaseinhibitorsinepithelioidinflammatorymyofibroblasticsarcomaharboringprrc2balkrearrangementacasereport
AT wangmiaomiao durableclinicalresponsetoalktyrosinekinaseinhibitorsinepithelioidinflammatorymyofibroblasticsarcomaharboringprrc2balkrearrangementacasereport
AT yechenyang durableclinicalresponsetoalktyrosinekinaseinhibitorsinepithelioidinflammatorymyofibroblasticsarcomaharboringprrc2balkrearrangementacasereport
AT sunli durableclinicalresponsetoalktyrosinekinaseinhibitorsinepithelioidinflammatorymyofibroblasticsarcomaharboringprrc2balkrearrangementacasereport
AT daiweiping durableclinicalresponsetoalktyrosinekinaseinhibitorsinepithelioidinflammatorymyofibroblasticsarcomaharboringprrc2balkrearrangementacasereport
AT zangyuansheng durableclinicalresponsetoalktyrosinekinaseinhibitorsinepithelioidinflammatorymyofibroblasticsarcomaharboringprrc2balkrearrangementacasereport